February 22, 2013
CURRICULUM VITAE
Name:
Robert Turner Schooley
Address:
6603 Mower Place, San Diego, CA 92130
Date of Birth:
November 10, 1949
Place of Birth:
Washington, D.C.
Education:
1970 B.S.
1974 M.D.
Washington and Lee University, Lexington, VA
The Johns Hopkins University School of Medicine, Baltimore, MD
Postdoctoral Training:
Internship and Residencies:
1974-1975
1975-1976
Intern in Medicine, The Johns Hopkins Hospital, Baltimore, MD
Assistant Resident in Medicine, The Johns Hopkins Hospital, Baltimore, MD
Research Fellowships:
1976-1977
1977-1978
1978-1979
1979-1981
1979-1981
Clinical Associate, Laboratory of Clinical Investigation,
National Institute of Allergy and Infectious Diseases,
National Institutes of Health, Bethesda, MD
Chief Clinical Associate, Laboratory of Clinical
Investigation, National Institute of Allergy and Infectious Diseases,
National Institutes of Health, Bethesda, MD
Medical Officer, Medical Virology Section, Laboratory of
Clinical Investigation, National Institute of Allergy and
Infectious Diseases, National Institutes of Health, Bethesda, MD
Clinical and Research Fellow, Infectious Disease Unit,
Massachusetts General Hospital, Boston, MA
Research Fellow in Medicine, Harvard Medical School, Boston, MA
Licensure and Certification:
1974-1981
1977
1979-1991
1981-1982
19902005-
Maryland State Board of Medical Examiners
Diplomat, American Board of Internal Medicine
Massachusetts State Board of Medical Examiners
New York State Board of Medical Licensure
Colorado State Board of Medical Examiners
Medical Board of California
1
Academic Appointments:
1981-1983
1983-1987
1987-1990
1990-2004
1994-2004
2002-2004
20052007 -
Instructor in Medicine, Harvard Medical School, Boston, MA
Assistant Professor of Medicine, Harvard Medical School, Boston, MA
Associate Professor of Medicine, Harvard Medical School, Boston, MA
Professor of Medicine, Head, Division of Infectious Diseases, University of
Colorado Health Sciences Center, Denver, CO.
Tim Gill Professor of Medicine, University of Colorado Health Sciences
Center, Denver, CO.
Director, Colorado Center for AIDS Research
Professor of Medicine and Head, Division of Infectious Diseases, University
of California, San Diego.
Academic Vice Chair, Department of Medicine, University of California,
San Diego
Hospital Appointments:
1981-1982
1983-1986
1987-1989
1990
1990-2006
1990- 2006
1990-2004
2005-
Clinical Assistant in Medicine, Massachusetts General Hospital, Boston, MA
Assistant in Medicine, Massachusetts General Hospital, Boston, MA
Assistant Physician, Massachusetts General Hospital, Boston, MA
Associate Physician, Massachusetts General Hospital, Boston, MA
Physician, University Hospital, Denver, CO
Staff Physician, Denver Veterans Affairs Medical Center, Denver, CO
Consultant, Denver Health & Hospitals, Denver, CO
Staff Physician, UCSD Healthcare
Other Professional Positions:
1980-1985
1982-1990
Consultant in Internal Medicine, Massachusetts Eye and Ear Infirmary,
Boston, MA
Consultant in Infectious Diseases, Harvard University Health Services,
Cambridge, MA
Awards and Honors:
19701980-3
19901995-present
1991
1993-present
1993-present
1992-present
1997-present
1999
Omicron Delta Kappa
New Investigator Award, NIAID, NIH
American Society for Clinical Investigation
Association of American Physicians
John Enders Memorial Lectureship, Infectious Disease Society of America
Who’s Who in the West
Who’s Who in Healthcare and Technology
Best Doctors in America
America’s Top Doctors
Bonfils-Stanton Foundation Award for Science or Medicine
2
1999-present Who’s Who in America
1999
Honorary Professor, Peking Union Medical College, Beijing, China
2007
Chief Residents’ Clinical Teaching Award, University of California, San
Diego
2009
Gold Doc Award, Arnold P. Gold Foundation
Major Committee Assignments:
National and International:
1985-1990
1990-1992
1992-1994
1989-1992
1989-1992
1990-1994
19901992-1996
1993-1995
1991-1995
1991-1994
1992-1995
1992-1996
19961994-1996
1994-1997
19941995-2000
1995-2002
1995-1996
1995-1999
19961996-1999
1997- 2003
Consultant, AIDS Study Sections, National Institutes of Health
Chairman, AIDS and Related Retrovirus A (Immunology and Pathogenesis)
Study Section, Division of Research Grants, National Institutes of Health
Member, AIDS and Related Retrovirus A (Immunology and Pathogenesis)
Study Section, Division of Research Grants, National Institutes of Health
Member, Infectious Disease Merit Review Study Section, Department of
Veterans Affairs
Chairman, Immune Based Therapy Working Group, AIDS Clinical Trials
Group, NIAID, NIH
Core Immunology Committee, AIDS Clinical Trials Group, NIAID, NIH
Scientific Advisory Committee, American Foundation for AIDS Research
(AMFAR)
Medical and Scientific Advisory Council, National Hemophilia Foundation
Chairman, Core Immunology Committee, AIDS Clinical Trials
Group, NIAID, NIH
AIDS Clinical Drug Development Committee (ACDDC), NIAID, NIH
Member, Governor's AIDS Council, State of Colorado
Member, Program Committee, Interscience Conference of Antimicrobial
Agents and Chemotherapy
Chair, Program Committee, US Conference on Human Retroviruses and
Related Infections, American Society for Microbiology
Member, Program Committee, US Conference on Human Retroviruses and
Related Infections, Foundation for Human Retroviruses
Member, National Task Force for AIDS Drug Development, Department of
Health and Human Services
Councilor, American Society for Clinical Investigation
Member, Executive Committee, AIDS Clinical Trials Group, NIAID, NIH
Chair, AIDS Panel, US-Japan Cooperative Medical Sciences Program, NIH
Chair, Executive Committee, AIDS Clinical Trials Group, NIAID, NIH
Member, Office of AIDS Research Advisory Counsel, Department of Health
and Human Services
Member, Scientific Program Committee, Infectious Diseases Society of
America
Member, External Advisory Committee, Case Western Reserve Center for
AIDS Research
Member, Fellowship and Young Investigator Awards Committee, Infectious
Diseases Society of America
Member, AIDS and Cancer Specimen Resource, National Cancer Institute
3
1997
1999-2005
2000-2003
2002-2008
2002-2004
20032004-2005
2004-2006
2008
20092010-2011
2010
20102011-2013
Chair, Scientific Program Committee, Infectious Diseases Society of
America
Member, Governing Council, International AIDS Society
Chair, Fellowship and Young Investigator Awards Committee, Infectious
Diseases Society of America
Member, Hepatitis Research Agenda Committee, AIDS Clinical Trials
Group, NIAID, NIH
Director, Colorado Center for AIDS Research
Coordinator for International Programs, AIDS Clinical Trials Group, NIAID,
NIH
Institute of Medicine Panel on Therapeutics in Resource Limited Settings
NIH Vaccine Research Center, Board of Scientific Counselors, NIH
Co-Director, American Association for the Study of Liver Diseases Single
Topic Conference, (Viral Hepatitis Therapy: Lessons to Be Learned from
HIV)
Member, Scientific Advisory Committee, University of Hong Kong AIDS
Research Center
Member, Drug Development and Resistance (DDR) Study Section, Division
of Extramural Activities, National Institutes of Health
Member, Reference Group on Medical Education, World Health
Organization
Member, Scientific Advisory Board, President’s Emergency Program for
AIDS Relief (PEPFAR), United States Department of State
Chair, Drug Development and Resistance (DDR) Study Section, Division of
Extramural Activities, National Institutes of Health
Medical School/Health Sciences Center:
1985-1988
1990-1991
1996-2002
2000-2001
2000-2004
2002-2004
2006-2009
2007200820092009-2010
Curriculum Design Committee, Identity and Defense, Oliver Wendell
Holmes Pathway, Harvard Medical School
Committee on Research Safety, University of Colorado Health Sciences
Center
Member, Faculty Senate, UCHSC School of Medicine
President, Faculty Senate, UCHSC School of Medicine
Member, Faculty Assembly, UCHSC
Member, Internship Selection Committee, Department of Medicine, UCHSC
School of Medicine
Institutional Biosafety Committee, UCSD
Member, Finance Committee, UCSD School of Medicine
Member, Space Committee, Department of Medicine, UCSD
Member, Steering Committee, UCSD Global Health Initiative
Chair, Institutional Biosafety Committee, UCSD
Hospital:
1984-1986
Subcommittee on Research Safety, Committee on Research, Massachusetts
General Hospital
4
1986-1988
1986-1989
2000-2002
2005-2008
2005-2006
Internship Selection Committee, Medical Services, Massachusetts General
Hospital
Subcommittee on Human Studies, Committee on Research, Massachusetts
General Hospital
Member, Medical Board, University of Colorado Hospital
Member, Infection Control Committee, UCSD Medical Center
Peer Review Coordinator for Infectious Diseases, UCSD Medical Center
Professional Societies:
1980-1985
1982-1996
19831984199019901992-2008
199520072008-
American College of Physicians
American Association of Immunologists
American Association for the Advancement of Science
Fellow, Infectious Disease Society of America
American Society for Clinical Investigation
American Society for Microbiology
Clinical Immunology Society
Association of American Physicians
American Society of Tropical Medicine and Hygiene
Fellow, Royal Society of Medicine, UK
Major Research Interests:
1. Viral Pathogenesis and therapy
2. Lymphocyte Activation and Regulation
3. Acquired Immune Deficiency Syndrome
4. International Medicine
Teaching Experience:
1980-1990
1981-1990
1981-1990
1982-1990
1982-1990
1984-1990
1984-1992
1985-1987
1985-1990
Lecturer, 4th Year Microbiology Course, Harvard Medical School
Attending Physician, Medical Service, Massachusetts General Hospital
Grand Rounds, Massachusetts General Hospital (Pediatrics, Medicine,
Dermatology, Surgery, Neurology, Pulmonary, Arthritis)
Lecturer, Postgraduate Courses, Massachusetts General Hospital Harvard
Medical School (Pediatrics, Neurology, Surgery, Primary Care,
Rheumatology, Internal Medicine, Infectious Disease, Surgical Oncology,
immunology, Anesthesia, Pediatric Anesthesia)
Supervisor, Postdoctoral Fellows in Virology
Lecturer, Microbiology-Pathophysiology Course 701, Harvard Medical
School
Lecturer, Infectious Disease, Arthritis Postgraduate Course, Brigham and
Women's Hospital Harvard Medical School
Course Development, Curriculum Design Committee, Identity and Defense,
Oliver Wendell Holmes Pathway, Harvard Medical School
Director, Fellowship Program, Infectious Disease Unit, Massachusetts
General Hospital
5
1990-2004
1990-2003
1990-2004
1997-2003
2002-2004
2002
2003
2005-
Medical Grand Rounds, University of Colorado Health Sciences Center
Lecturer, Postgraduate Medical Education Courses, University of Colorado
Health Sciences Center
Section Leader, Pathophysiology of Infectious Diseases (Microbiology
6000), University of Colorado Health Sciences Center
Lecturer, Pharmacology 6000
Course Director, Pathophysiology of Infectious Diseases (Microbiology
6000), University of Colorado Health Sciences Center
Lecturer, Microbiology 6000, University of Colorado Health Sciences
Center
Lecturer, Virology Graduate Course, University of Colorado Health Sciences
Center
Lecturer, SOM 208, Principles of Human Disease
Principal Clinical and Hospital Service Responsibilities:
1981-1990
1982-1990
1990-2006
1990-2006
1991-2004
2005-
Attending Physician, Medical Service, Massachusetts General Hospital
Consultant in Infectious Diseases, Transplant Program, Massachusetts
General Hospital
Physician, University of Colorado Hospital, Denver, CO
Staff Physician, Denver Veterans Affairs Medical Center, Denver, CO
Staff Physician, Denver Health & Hospital, Denver, CO
Staff Physician, UCSD Medical Center
Major Administrative Responsibilities:
1985-1990
1989-1990
1990-2004
2002-2004
20052005-2006
20052012-
Director, Postdoctoral Fellowship Training Program, Infectious Disease
Unit, Massachusetts General Hospital
Acting Co-Director, Clinical Center, Harvard AIDS Institute
Director, Infectious Disease Division, University of Colorado Health
Sciences Center
Director, Colorado Center for AIDS Research
Director, Division of Infectious Diseases, University of California, San
Diego
Director, Postdoctoral Fellowship Training Program, University of
California, San Diego
Co-Director, International Program, Center for AIDS Research, University
of California, San Diego
Associate Director, Center for AIDS Research, University of California, San
Diego
Editorial Boards:
1996- 2001
1987-1998
19871992-1999
Antimicrobial Agents and Chemotherapy
Biotherapy
Journal of Acquired Immune Deficiency Syndromes
Clinical and Diagnostic Laboratory Immunology
6
19942002-
AIDS
Section Editor, Clinical Infectious Diseases (HIV/AIDS)
Student Instructional Activities
Postdoctoral Fellows
Year
Name
Current Position
1980-2
Joseph B. Garner, M.D.
Associate Professor of Medicine
University of Connecticut School of Medicine
1982-4
Richard Blumberg, M.D.
Professor of Medicine
Harvard Medical School
1984-7
Bruce D. Walker, M.D.
Professor of Medicine
Harvard Medical School
1987-8
Laura Fisher, M.D.
Associate Professor of Medicine
Cornell University School of Medicine
1986-90
Tyler Curiel, M.D.
Professor of Medicine
Director, San Antonio Cancer Institute
Associate Dean
University of Texas, San Antonio
1987-90
Daniel R. Kuritzkes, M.D.
Professor of Medicine
Harvard Medical School
1990-3
Elizabeth McFarland, M.D. Associate Professor of Pediatrics
(with Daniel Kuritzkes)
University of Colorado Health Sciences Center
2002-4
David L. Wyles, M.D.
Assistant Professor of Medicine
(with Constance A. Benson) University of California, San Diego
UCSD Mentoring and Supervision
Postdoctoral Fellows
2005- 2008
Sanjay Mehta, M.D.
Immunopathogenesis of Leishmania Infection
Robert C. Huang, M.D.
2006- 2007 Development of a Green Fluorescent Protein Transfected Leishmania-based
model for the study of Leishmanial infection
Julio Gutierrez, M.D., Ph.D.
7
2009-
Pathogenesis and treatment of HCV infection
Cathy Logan, M.D.
2010
Rapid Point-of-Care Diagnostics for Resource Limited Settings
UCSD Medical Students
2006
Carly Guthrie
Malarial parasite burden in HIV-1 co-infected patients in Manaus, Brazil
2006
Jacob Durant
Development of a Multiplexed Antigen and Antibody Detection System for
the Diagnosis of Infectious Diseases
2007
Marika Orlov
Epidemiology and medical impact of P. falciparum and T. solium in
Mozambique
Pre-doctoral Students UCSD Graduate School
2006
Leslie Crews, Ph.D. Candidate
Minor Proposition Thesis Committee Member
Role of B Lymphocyte Receptors in the Extrahepatic Signaling Effects of
Hepatitis C Virus
2006
Nisha Maranthe, Ph.D. Candidate
Minor Proposition Thesis Committee Member
The role of NS4B in the replication of Hepatitis C virus
2007
Morgan A. Pence, Ph. D. Candidate
Minor Proposition Thesis Committee Member
Inhibition of Granzyme-mediated Apoptosis in Hepatitis C Infection
Ph.D Sponsor
2008-
Marika Orlov
Pathogenesis and Clinical Implications of the Interactions Between HIV-1
and P. falciparum
8
Bibliography
I. Original Articles
1.
Kimberg DV, Field M, Gershon E, Schooley RT and Henderson A. Effects of cycloheximide
on the response of intestinal mucosa to cholera enterotoxin. J Clin Invest. 1973; 52:1376-83.
2.
Schooley RT, Wagley PF and Lietrnan PS. Edema associated with ibuprofen therapy.
JAMA. 1977; 237:1716-7.
3.
Lightman NI and Schooley RT. Adult-onset acid maltase deficiency. Case report of an
adult with severe respiratory difficulty. Chest. 1977; 72:250-2.
4.
Haynes BF, Schooley RT, Grouse JE, Payling-Wright CR, Dolin R and Fauci AS.
Characterization of thymus-derived lymphocyte subsets in acute Epstein-Barr virus-induced
infectious mononucleosis. J Immunol. 1979; 122:699-702.
5.
Haynes BF, Schooley RT, Payling-Wright CR, Grouse J, Dolin R and Fauci AS.
Emergence of suppressor cells of immunoglobulin synthesis during acute Epstein-Barr
virus-induced infectious mononucleosis. J Immunol. 1979; 123:2095-101.
6.
Schooley RT, Haynes BF, Payling-Wright CR, Grouse J, Dolin R and Fauci AS.
Mechanism of Epstein-Barr virus-induced human B-lymphocyte activation. Cellular
Immunol. 1980; 56:518-25.
7.
Cupps TR, Cotton DJ, Schooley RT and Fauci AS. Facial erysipelas in the
immunocompromised host. Report of two cases. Arch Dermatol. 1981; 117:47-9.
8.
Wasson DL, Loegering DA, Solley GO, Moore SB, Schooley RT, Fauci AS and Gleich GJ.
Elevated serum levels of the eosinophil granule major basic protein in patients with
eosinophilia. J Clin lnvest. 1981; 67:651-61.
9.
Flaum MA, Schooley RT, Fauci AS and Gralnick HR. A clinicopathologic correlation of
the idiopathic hypereosinophilic syndrome. I. Hematologic manifestations. Blood. 1981;
58:1012-20.
10.
Schooley RT, Flaum MA, Gralnick HR and Fauci AS. A clinicopathologic correlation of
the idiopathic hypereosinophilic syndrome. II. Clinical manifestations. Blood. 1981;
58:1021-6.
11.
Schooley RT, Haynes BF, Grouse J, Payling-Wright CR, Fauci AS and Dolin R.
Development of suppressor T-lymphocytes for Epstein-Barr virus-induced B-lymphocyte
outgrowth during acute infectious mononucleosis: Assessment by two quantitative systems.
Blood. 1981; 57:510-7.
9
12.
Rubin RH, Carney WP, Schooley RT, Colvin RB, Burton RC, Hoffman RA, Hansen WP,
Cosimi AB, Russell PS and Hirsch MS. The effect of infection of T-lymphocyte
subpopulations: a preliminary report. Int J lmmunopharmacol. 1981; 3:307-12.
13.
Dolin R, Reichman RC, Roessner KD, Tralka TS, Schooley RT, Gary W and Morens D.
Detection by immune electron microscopy of Snow Mountain agent of acute viral
gastroenteritis. J Inf Dis. 1982; 146:184-9.
14.
Thorley-Lawson DA, Schooley RT, Bhan AK and Nadler LM. Epstein-Barr virus
superinduces a new human B cell differentiation antigen (B-LAST 1) expressed on
transformed lymphoblasts. Cell. 1982; 30:415-25.
15.
Geraci JR, St. Austin DJ, Barker, IK, Webster RG, Hinshaw VS, Bean WJ, Ruhnke HL,
Prescott JH, Early G, Baker AS, Madoff S and Schooley RT. Mass mortality of harbor
seals: pneumonia associated with influenza A virus. Science. 1982; 215:1129-31.
16.
Thorley-Lawson DA, Geilinger K and Schooley RT. Monoclonal antibody against EBVassociated transformation antigen detected in vitro and in vivo. Protides Biol Fluid Colloq.
1982; 29:739-42.
17.
Quinnan GV, Schooley RT, Dolin R, Ennis FA, Gross P and Gwaltney JM. Serological
responses and systemic reactions in adults with monovalent A/USSR/77 and trivalent
A/USSR/77-A/Texas/77-B/Hong Kong/72 influenza vaccine. Rev Infect Dis. 1983; 5:74857.
18.
Gottdiener JS, Maron BJ, Schooley RT, Harley JB, Roberts WC and Fauci AS. Twodimensional echocardiographic assessment of the idiopathic hyper-eosinophilic syndrome.
Anatomic basis of rnitral regurgitation and peripheral embolization. Circulation. 1983;
67:572-8.
19.
Slovin SF, Schooley RT and Thorley-Lawson DA. Analysis of cellular immune response to
EBV by using cloned T cell lines. J Immunol. 1983; 130:2127-32.
20.
Schooley RT, Hirsch MS, Colvin R.B, Cosimi AB, Tolkoff-Rubin NE, McCluskey RT,
Burton RC, Russell PS, Herrin JT, Delmonico FL, Giorgi JV, Henle W and Rubin RH.
Association of herpes virus infections with T-lymphocyte subset alterations,
glomerulopathy, and opportunistic infections following renal transplantation. N Engl J
Med. 1983; 308:307-13.
21.
Schooley RT, Byington R and Falk Jr. LA. Phenotypic analysis of New World primate
mononuclear cell surface antigens. J Med Primatology. 1983; 12:30-40.
22.
Hirsch MS, Schooley RT, Cosimi AB, Russell PS, Delmonico FL, Tolkoff-Rubin NE,
Herrin JT, Cantell K, Farrell ML, Rota TR and Rubin RH. Effects of interferon-alpha on
cytomegalovirus reactivation syndromes in renal transplant recipients. N Engl J Med.
1983; 308:1489-93.
10
23.
Delmonico FL, Cosimi AB, Jaffers GJ, Schooley RT, Rubin RH, Tolkoff-Rubin N, Fang
LT and Russell PS. Immunological monitoring of diabetic and nondiabetic recipients of
renal allografts. J Surg Research. 1983; 35:271-6.
24.
Hochberg FH, Miller G, Schooley RT, Hirsch MS, Fiorino P and Henle W. Centralnervous-system lymphoma related to Epstein-Barr virus. N Engl J Med. 1983; 309:745-8.
25.
Falk Jr. LA, Silva D, Byington R and Schooley RT. Long-term propagation of New World
primate T-lymphocytes in vitro. Proceedings of the Fifteenth International Leukocyte
Culture Conference. Intercell Communicat in Leucocyte Function. 1983; 577-80.
26.
Blazar BA, Strome M and Schooley RT. Interferon and natural killing of human lymphoma
lines following induction of the Epstein-Barr virus cycle of superinfection. J Immunol.
1984; 132:816-20.
27.
Schooley RT, Densen P, Harmon D, Felsenstein D, Hirsch MS, Henle H and Weitzman S.
Antineutrophil antibodies in infectious mononucleosis. Am J Med. 1984; 76:85-90.
28.
Garner JG, Colvin RB and Schooley RT. A flow cytometric technique for quantitation of
B-cell activation. J Immunol Methods. 1984; 67:37-51.
29.
Garner JG, Hirsch MS and Schooley RT. Prevention of Epstein-Barr virus-induced B-cell
outgrowth by interferon alpha. Infect & Immuno. 1984; 43:920-4.
30.
Schooley RT, Arbit DI, Henle W and Hirsch MS. T-Lymphocyte Subset Interactions in the
Cell-Mediated Immune Response to Epstein-Barr Virus. Cellular Immun. 1984; 86:40212.
31.
Kelly AP, Schooley RT, Rubin RH and Hirsch MS. Effect of interferon alpha on natural
killer cell cytotoxicity in kidney transplant recipients. Clin Immuno & Immunopatho.
1984; 32:20-8.
32.
Ho DD, Schooley RT, Rota TR, Kaplan JS, Flynn T, Salahuddin SZ, Gonda MA and Hirsch
MS. HTLV-III in the semen and blood of a healthy homosexual man. Science. 1984;
226:451-3.
33.
Lind SE, Gross PL, Andiman WA, Stone GC, Schooley RT and Harris NL. Malignant
Lymphoma Presenting as Kaposi's Sarcoma in a Homosexual Man with the Acquired
Immunodeficiency Syndrome. Ann Intern Med. 1985; 102:338-40.
34.
Miller G, Grogan E, Fischer DK, Niederman JC, Schooley RT, Henle W, Lenoir G and Liu
CR. Antibody responses to two Epstein-Barr virus nuclear antigens defined by gene
transfer. N Engl J Med. 1985; 312:750-5.
35.
Thorley-Lawson DA, Nadler LM, Bhan AK and Schooley RT. BLAST-2 (EBVCS), an
early cell surface marker of human B cell activation, is superinduced by Epstein-Barr virus.
J Immunol. 1985; 134:3007-12.
11
36.
Edson CM, Hosler BA, Poodry CA, Schooley RT, Waters DJ and Thorley-Lawson DA.
Varicella-zoster virus envelope glycoproteins: biochemical characterization and
identification in clinical material. Virol. 1985; 145:62-71.
37.
Ho DD, Rota TR, Schooley RT, Kaplan JC, Allen JD, Groopman JE, Resnick L,
Felsenstein D, Andrews CA and Hirsch MS. Isolation of HTLV-III from cerebrospinal
fluid and neural tissues of patients with neurologic syndromes related to Acquired
Immunodeficiency Syndrome. N Engl J Med. 1985; 313:1493-7.
38.
Hirsch MS, Wormser G, Schooley RT, Ho DD, Felsenstein D, Hopkins CC, Joline C,
Duncanson F, Sargadharan MG, Saxinger C and Gallo RC. Risk of nosocomial infection
with human T-lymphotropic virus-III (HTLV-III). N Engl J Med. 1985; 312:1-4.
39.
Ho DD, Hartshorn KL, Rota TR, Andrews CA, Kaplan JC, Schooley RT and Hirsch MS.
Recombinant human interferon alpha-A suppresses HTLV-III replication in vitro. Lancet.
1985; 1:602-4.
40.
Sandstrom EG, Schooley RT, Ho DD, Byington R, Sarngadharan MG, MacLane ME, Essex
M, Gallo RC and Hirsch MS. Detection of human anti-HTLV-III antibodies by indirect
immunofluorescence using fixed cells. Transfusion. 1985; 25:308-12.
41.
Felsenstein D, D'Amico DJ, Hirsch MS, Neumeyer DA, Cederberg DM, de Miranda P and
Schooley RT. Treatment of cytomegalovirus retinitis with 9-[2-Hydroxy-1(Hydroxymethyl)ethoxymethyl] guanine (BWB759U). Ann Intern Med. 1985; 103:37780.
42.
Ho DD, Byington RE, Schooley RT, Flynn T, Rota TR and Hirsch MS. Infrequency of
isolation of HTLV-III virus from saliva in AIDS [letter]. N Engl J Med. 1985; 313:1606.
43.
Schooley RT, Carey RW, Miller G, Henle W, Eastman R, Mark EJ, Kenyon K, Wheeler EO
and Rubin RH. Chronic Epstein-Barr virus infection associated with fever and interstitial
pneumonitis. Clinical and serologic features and response to antiviral chemotherapy. Ann
Intern Med. 1986; 104:636-43.
44.
Blumberg RS, Sandstrom EG, Paradis TJ, Neumeyer DN, Sarngdharan MG, Hartshorn KL,
Byington RE, Hirsch MS and Schooley RT. Detection of HTLV-III related antigens and
anti-human anti-HTLV-III antibodies by anticomplementary immunofluorescence. J Clin
Micro. 1986; 23:1072-7.
45.
Whitley RJ, Alford CA, Hirsch MS, Schooley RT, Luby JP, Aoki FY, Hanley D, Nahmias
AJ and Soong SJ. Vidarabine versus acyclovir therapy in herpes simplex encephalitis. N
Engl J Med. 1986; 314:144-9.
46.
Vogt MW, Witt DJ, Craven DE, Byington R, Crawford DF, Schooley RT and Hirsch MS.
Isolation of HTLV-III/LAV from cervical secretions of women at risk for AIDS. Lancet.
1986; 1:525-7.
12
47.
Vogt MW, Ho DD, Bakar SR, Gilbard JP, Schooley RT and Hirsch MS. Safe disinfection
of contact lenses after contamination with HTLV-III. Ophthalmol. 1986; 93:771-4.
48.
Hartshorn KL, Sandstrom EG, Neumeyer D, Paradis TJ, Chou TC, Schooley RT and Hirsch
MS. Synergistic inhibition of HTLV-III replication in vitro by phosphonoformate and
recombinant alpha-A interferon. Antimicrob Ag Chemoth. 1986; 30:189-9 1.
49.
Sandstrom EG, Andrews CA, Schooley RT, Byington R and Hirsch MS. Suppression of
concanavalin A-induced blastogenesis by HTLV-III-infected H9 cells. Clin Immuno &
Immunopath. 1986; 40:253-8.
50.
D'Amico DJ, Talamo JH, Felsenstein D, Hirsch MS, Albert DM and Schooley RT.
Ophthalmoscopic and histologic findings cytomegalovirus retinitis treated with BWB759U. Arch Ophthalmol. 1986; 104:1788-93.
51.
Ho DD, Sarngadharan MG, Hirsch MS, Schooley RT, Rota TR, Kennedy RC, Chanh TC
and Sato VL. HIV neutralizing antibodies recognize several conserved domains on the
envelope glycoproteins. J Virology. 1987; 61:2024-8.
52.
Hartshorn KL, Vogt MW, Chou TC, Blumberg RS, Byington R, Schooley RT and Hirsch
MS. Synergistic inhibition of human immunodeficiency virus in vitro by azidothymidine
and recombinant alpha-A interferon. Antimicro Ag Chemoth. 1987; 31:168-72.
53.
Vogt MW, Hartshorn KL, Furman PA, Chou TC, Fyfe JA, Coleman LA, Crumpacker C,
Schooley RT and Hirsch MS. Ribavirin antagonizes the effect of azidothymidine (AZT) on
HIV replication. Science. 1987; 235:1376-9.
54.
Vogt MW, Witt DJ, Craven DE, Byington R, Crawford DF, Hutchison MS, Schooley RT
and Hirsch MS. Isolation Patterns of the Human Immunodeficiency Virus (HIV) from
cervical secretions during the menstrual cycle of women at risk for AIDS. Ann Intern Med.
1987;106:380-2.
55.
Miller G, Grogan E, Rowe D, Rooney C, Heston L, Eastman R, Andiman W, Niederman J,
Lenoir G, Henle W, Sullivan J, Schooley R, Vossen J, Straus S and Issekutz T. Selective
lack of antibody to a component of EB Nuclear Antigen in patients with chronic active
Epstein-Barr virus infection. J Infect Dis. 1987; 156:26-35.
56.
Walker BD, Chakrabarti S, Moss B, Paradis TJ, Flynn T, Durno AG, Blumberg RS, Kaplan
JC, Hirsch MS and Schooley RT. HIV-specific cytotoxic T lymphocytes in seropositive
individuals. Nature. 1987; 328:345-8.
57.
Fischl MA, Richman DD, Grieco M, Gottlieb MS, Volberding P, Laskin D, Leedom JM,
Schooley RT, Groopman J, Mildvan D, Jackson GG, Durack D, King D and the AZT
Collaborative Working Group. The efficacy of azidothymidine (AZT) in the treatment of
patients with AIDS and AIDS-related complex: a double-blind placebo-controlled trial. N
Engl J Med. 1987; 317:185-91.
13
58.
Richman DD and the AZT Collaborative Working Group. The toxicity of 3'-azido'deoxythymidine (azidothymidine) in the treatment of patients with AIDS and AIDS-related
complex: a double-blind, placebo-controlled trial. N Engl J Med. 1987; 317:192-7.
59.
Blumberg RS, Paradis T, Byington R, Henle W, Hirsch MS and Schooley RT. Effects of
HIV on the cellular immune response to Epstein-Barr virus in homosexual men:
characterization of the cytotoxic response and lymphokine production. J Infect Dis. 1987;
155:877-90.
60.
Hartshorn KL, Neumeyer D, Vogt MW, Schooley RT and Hirsch MS. Activity of
interferons alpha, beta, and gamma against human immunodeficiency virus replication in
vitro. AIDS Res Hum Retroviruses. 1987; 3:125-33.
61.
Blumberg RS, Hartshorn KL, Ardman B, Kaplan JC, Paradis TJ, Vogt M, Hirsch MS and
Schooley RT. Dot immunobinding assay for detection of human immunodeficiency virus
(HIV) associated antigens. J Clin Micro. 1987; 25:1989-92.
62.
Whitley RJ, Alford CA, Hirsch MS, Schooley RT, Luby JP, Aoki FY, Hanley D, Nahmias
AJ and Soong SJ. Factors indicative of outcome in a comparative trial of acyclovir and
vidarabine for biopsy-proven herpes simplex encephalitis. Infection. 1987; 15 Suppl 1:S38.
63.
Blumberg RS, Paradis TJ, Crawford D, Byington RE, Hirsch MS and Schooley RT. Effects
of human immunodeficiency virus on the cytotoxic response to Epstein-Barr Virus (EBV)
transformed B-lymphocytes. AIDS Res and Hum Retro. 1987; 3:303-15.
64.
Wong KW, D'Amico DJ, Hedges TR 3rd, Soong HK, Schooley RT and Kenyon KR. Ocular
involvement associated with chronic Epstein-Barr virus disease. Arch Ophthalmol. 1987;
105:788-92.
65.
Blumberg RS, Paradis TJ, Hartshorn KL, Vogt M, Ho DD, Hirsch MS, Leban J, Sato VL
and Schooley RT. Antibody-dependent cell-mediated cytotoxicity (ADCC) against cells
infected with the Human Immunodeficiency Virus. J Infect Dis. 1987; 156:878-84.
66.
Kaplan JC, Crawford DC, Durno AG and Schooley RT. Inactivation of Human
Immunodeficiency Virus (HIV) by Betadine. Infect Control. 1987; 8:412-4.
67.
Gibas A, Dienstag JL, Schafer AI, Delmonico F, Bynum TE, Schooley RT, Rubin RH and
Cosimi AB. The Cure of Hemophilia A by Orthotopic Liver Gastroenterology. 1988;
95:192-4.
68.
Tuazon TV, Schneeberger EE, Bhan AK, McCluskey RT, Cosimi AB, Schooley RT, Rubin
RH and Colvin RB. Mononuclear cells in acute allograft glomerulopathy. Am J Path.
1987; 129:119-32.
69.
Pomerantz RJ, Kuritzkes DR, de la Monte SM, Rota TR, Baker AS, Albert D, Bor DH,
Feldman EL, Schooley RT and Hirsch MS. Infection of the Retina by Human
Immunodeficiency Virus Type I (HIV-1). N Engl J Med. 1987; 317:1643-7.
14
70.
de la Monte SM, Ho DD, Schooley RT, Hirsch MS and Richardson EP Jr. Subacute
encephalomyelitis of AIDS and its relation to HTLV-III infection. Neurology. 1987;
37:562-9.
71.
Fisher RA, Bertonis JM, Meier W, Johnson VA, Costopoulos DS, Liu T, Tizard R, Walker
BD, Hirsch MS, Schooley RT and Flavell RA. HIV infection is blocked in vitro by
recombinant soluble T4. Nature. 1988; 331:76-8.
72.
Holmes GP, Kaplan JE, Gantz NM, Komaroff AL, Schonberger LB, Straus SE, Jones JE,
DuBois RE, Cunningham-Rundles C, Pahwa S, Tosato G, Zegans LS, Purtilo DT, Brown
N, Schooley RT and Brus I. Chronic Fatigue Syndrome: A working case definition.
Annals Intern Med. 1988; 108:387-9.
73.
Fischl MA, Richman DD, Causey DM, Grieco MH, Bryson Y, Mildvan D, Laskin OL,
Groopman JE, Volberding PA, Schooley RT, et. al. Prolonged zidovudine therapy in
patients with AIDS and advanced AIDS-related complex. JAMA. 1989; 262:2405-10.
74.
Chernow B, Schooley RT, Dracup K, Napolitano LM, Stanford GG and Klibanski A.
Serum prolactin concentrations in patients with the acquired immunodeficiency syndrome.
Critical Care Med. 1990; 18:440-1.
75.
Walker BD, Flexner C, Paradis TJ, Fuller TC, Hirsch MS, Schooley RT and Moss B. HIV1 reverse transcriptase is a target for cytotoxic T-lymphocytes in infected individuals.
Science. 1988; 240:64-6.
76.
Vogt MW, Durno AG, Chou TC, Coleman LA, Paradis TJ, Schooley RT, Kaplan JC and
Hirsch MS. Synergistic interaction of 2',3'- dideoxycytidine (ddCyd) and recombinant
interferon-alpha-A (r-IFN-alpha-A) on replication of HIV-1. J Infect Dis. 1988; 158:37885.
77.
Interferon Alpha Study Group. A randomized placebo-controlled trial of recombinant
human interferon alpha 2a in patients with AIDS. J AIDS. 1988; 1:111-8.
78.
D'Amico DJ, Skolnik PR, Kosloff BR, Pinkston P, Hirsch MS and Schooley RT.
Resolution of cytomegalovirus retinitis with zidovudine therapy. Case Report. Arch
Opthalmol. 1988; 106:1168-9.
79.
Jones JF, Williams M, Schooley RT, Robinson C and Glaser R. Antibodies to Epstein-Barr
Virus-Specific DNase and DNA Polymerase in the Chronic Fatigue Syndrome. Arch Intern
Med. 1988; 148:1957-60.
80.
de la Monte SM, Gabuzda DH, Ho DD, Brown RH Jr, Hedley-Whyte ET, Schooley RT,
Hirsch MS and Bhan AK. Peripheral neuropathy in the acquired immunodeficiency
syndrome. Annals of Neurology. 1988; 23:485-92.
81.
Murray HW, DePamphilis J, Schooley RT and Hirsch MS. Circulating interferon-gamma
in AIDS patients treated with interleukin-2 [letter]. N Engl J Med. 1988; 318:1538-9.
15
82.
Merigan TC, Skowron G, Bozzette S, Richman D, Uttamchandani R, Fischl M, Schooley
RT, Hirsch MS, Soo W, Pettinelli C, Schaumburg H and the ddC Study Group of the AIDS
Clinical Trials Group. Circulating p24 antigen levels and responses to Dideoxycytidine in
human immunodeficiency virus (HIV) infections. A Phase I-II Study. Ann Intern Med.
1989; 110:189-94.
83.
Johnson VA, Barlow MA, Chou TC, Fisher RA, Walker BD, Hirsch MS and Schooley RT.
Synergistic inhibition of human immunodeficiency virus type I (HIV-1) replication in vitro
by recombinant soluble CD4 and 3'-azido-3'-deoxythymidine. J Inf Dis. 1989; 159:837-44.
84.
Chao BH, Costopoulos DS, Curiel T, Bertonis JM, Chisholm P, Williams C, Schooley RT,
Rosa JJ, Fisher RA and Maraganore JM. A 113 -amino acid fragment of CD4 produced in
Escherichia coli blocks human immunodeficiency virus-induced cell fusion. J Biol Chem.
1989; 264:5812-7.
85.
Walker BD, Flexner C, Birch-Limberger K, Fisher L, Paradis TJ, Aldovini A, Young R,
Moss B and Schooley RT. Long-term culture and fine specificity of human cytotoxic Tlymphocyte clones reactive with HIV-1. Proc Natl Acad Sci, USA. 1989; 86:9514-8.
86.
Schooley RT, Merigan TC, Gaut P, Hirsch MS, Holodniy M, Flynn T, Liu S, Byington RE,
Henochowicz S, Gubish E. A Phase I/II escalating dose trial of recombinant soluble CD4
therapy in patients with AIDS or AIDS Related Complex. Ann Intern Med. 1990;
112:247-253.
87.
Surman OS, Flynn T, Schooley RT, Baer L, Parker S, Hirsch MS and Davis LG. A doubleblind, placebo-controlled study of oral acyclovir in postherpetic neuralgia. Psychosomatics.
1990; 31:287-92.
88.
Goldfeld AE, Birch-Limberger K, Schooley RT and Walker BD. HIV- 1 infection does not
induce tumor necrosis factor-alpha or interferon-beta gene transcription. JAIDS. 1991;
4:41-7.
89.
van der Horst C, Joncas J, Ahronheim G, Gustafson N, Stein G, Gurwith M, Fleisher G,
Sullivan J, Sixbey J, Roland S, Fryer J, Champney K, Schooley R, Sumaya C and Pagano J.
Lack of effect of peroral acyclovir for the treatment of acute infectious mononucleosis. J
Infect Dis. 1991; 164:788-92.
90.
Conway BD, Tomford WW, Mankin HJ, Hirsch MS and Schooley RT. Radiosensitivity of
HIV-1: Potential application to sterilization of bone allografts. AIDS. 1991; 5:608-9.
91.
Chen YM, Zhang XQ, Dahl CE, Samuel KP, Schooley RT, Essex M and Papas TS.
Delineation of type-specific regions on the envelope glycoproteins of human T-cell
leukemia viruses. J Immunol. 1991; 147:2368-76.
92.
Zhang XQ, Yang L, Ho DD, Kuritzkes DR, Chen IS, Ching WT, Chen YM and Schooley
RT. Human T-lymphotropic virus types I- and II-specific antibody-dependent cellular
cytotoxicity: strain specificity and epitope mapping. J Infect Dis. 1992; 165:805-12.
16
93.
Leff JA, Oppegard MA, Curiel TJ, Brown KS, Schooley RT and Repine JE. Progressive
increases in serum catalase activity in advancing human immunodeficiency virus infection.
Free Radical Biol and Med. 1992; 13:143 -9.
94.
Turner S, Tizard R, DeMarinis J, Pepinsky RB, Zullo J, Schooley RT and Fisher R.
Resistance of primary isolates of human immunodeficiency virus type 1 to neutralization by
soluble CD4 is not due to lower affinity with the viral envelope glycoprotein gp 120. Proc
Nat Acad Sci. 1992; 89:1335-9.
95.
Hibberd PL, Tolkoff-Rubin NE, Cosimi AB, Schooley RT, Isaacson D, Doran M,
Delvecchio A, Deirnonico FL, Auchincloss H Jr and Rubin RH. Symptomatic
cytomegalovirus disease in the cytomegalovirus antibody serpositive renal transplant
recipient treated with OKT3. Transplantation. 1992; 53:68-72.
96.
Conway BD, Baskar P, Bechtel LJ, Kaplan JC, Hirsch MS, Schooley RT and Pincus SH.
Eosinophils as host cells for HIV-1. Arch Virol. 1992; 127:373-7.
97.
Curiel TJ, Wong JT, Gorczxya PF, Schooley RT and Walker BD. CD4+ human
immunodeficiency virus type 1 (HIV-1) envelope-specific cytotoxic T lymphocytes derived
from the peripheral blood of an HIV-1-infected individual. AIDS Res Hum Retroviruses.
1993; 9:61-8.
98.
Choi S, Lagakos SW, Schooley RT and Volberding PA. CD4+ lymphocytes are an
incomplete surrogate marker for clinical progression in persons with asymptomatic HIV
inaction taking zidovudine. Ann Intern Med. 1993; 118:674-80.
99.
McFarland EJ, Curiel TJ, Schoen DJ, Rosandich ME, Schooley RT and Kuritzkes DR.
Cytotoxic T lymphocyte lines specific for human immunodeficiency virus type I gag and
reverse transcriptase derived from a vertically infected child. J Infect Dis. 1993; 167:71923.
100.
Ho DD, Cao Y, Zhu T, Farthing C, Wang N, Gu G, Schooley RT and Daar ES.
Idiopathic CD4+ T-lymphopenia - immunodeficiency without evidence of HIV infection.
New Engl J Med. 1993; 328:380-5.
101.
Hibberd PL, Surman OS, Bass M, Tolkoff-Rubin NE, Cosimi AB, Schooley RT, Doran M,
Delvecchio A, Rosal M and Rubin R. Psychiatric disease and cytomegaloviras viremia in
renal transplant recipients. Phychosomatics. 1995; 36:561-3.
102.
Larder BA, Kohli A, Bloor S, Kemp SD, Harrigan PR, Schooley RT, Lange JM,
Pennington KN, St. Clair MH and the protocol 34, 225-02 Collaborative Group. Human
immunodeficiency virus type I drug susceptibility during zidovudine (AZT) monotherapy
compared with AZT plus 2',3'-dideoxycytidine combination therapy. J Virol. 1996;
70:5922-9.
103.
Schooley RT, Campbell TB, Kuritzkes DR, Blaschke T, Stein DS, Rosandich ME, Phair J,
Pottage JC, Messari FA, Collier A, Kahn J and the ACTG 184 Protocol Team. A Phase I
17
Study of Combination Therapy with L-697, 661 and Zidovudine. J AIDS & Human
Retrovirology. 1996; 12:363-70.
104.
Schooley RT, Raniirez-Ronda C, Lange JMA, Cooper DA, Lavelle J, Lefkowitz L, Moore
M, Larder BA, St. Clair M, Mulder JW, McKinnis R, Pennington KN, Harrigan PR,
Kinghorn I, Steel H, Rooney JF and the Wellcome Resistance Study Collaborative Group.
Virologic and Immunologic Benefits of Initial Combination Therapy with Zidovudine and
Zalcitabine or Didanosine Compared to Zidovudine Monotherapy. J Infect Dis. 1996;
173:1354-66.
105.
Connick E, Marr DG, Zhang XQ, Clark SJ, Saag MS, Schooley RT and Curiel TJ.
HIV-specific cellular and humoral immune responses in primary HIV infection. AIDS Res
Hum Retroviruses. 1996; 12:1129-40.
106.
Hammer SM, Katzenstein DA, Hughes MD, Gundacker H, Schooley RT, Haubrich RH,
Henry WK, Lederman MM, Phair JP, Niu M, Hirsch MS and Merigan TC. A trial
comparing nucleoside monotherapy with combination therapy in HIV- infected adults with
CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study
175 Team. N Engl J Med. 1996; 335:1081-90.
107.
Uherova P, Connick E, MaWhinney S, Schlichtemeier R, Schooley RT and Kuritzkes DR.
In vitro effect of interleukin-12 on antigen-specific lymphocyte proliferative responses from
persons infected with human immunodeficiency virus type 1. J Infect Dis. 1996; 174:4839.
108.
Zhang X, Fitzpatrick L, Badaro R and Schooley RT. Seroprevalence of HHV-8 in Patients
with and at Risk for Kaposi's Sarcoma in the US and Brazil:. J Acquired Immune
Deficiency Syndromes & Human Retrovirology. 1997; 14:A22.
109.
Hughes MD, Daniels MJ, Fischl MA, Soyeon K and Schooley RT. CD4 Cell Count as a
Surrogate Endpoint in HIV Clinical Trials: A Meta-Analysis of Studies of the AIDS
Clinical Trials Group. AIDS. 1998; 12:1823-32.
110.
McFarland EJ, Harding PA, MaWhinney S, Schooley RT and Kuritzkes DR. In vitro
effects of interleukin-12 on human immunodeficiency virus type 1 (HIV-1) specific
cytotoxic T-lymphocyte lines from HIV-1 infected children. J Immun. 1998; 161:513-9.
111.
Mitsuyasu RT, Skolnik PR, Cohen SR, Conway B, Gill MJ, Jensen PC, Pulvirenti JJ, Slater
LN, Schooley RT, Thompson MA, Torres RA, Tsoukas CM, Salgo M, Delora P, Shear M,
Beattie D, Nestle J, Wolfarth C, Craig C and Duff FP. Activity of the soft gelatin
formulation of saquinavir in combination therapy in antiretroviral-naive patients. AIDS.
1998; 12:F103-9.
112.
Zhang XQ, Fitzpatrick L, Campbell TB, Badaro R, Schechter M, Melo MD, Brites C,
Pedral-Sampaio D and Schooley RT. Comparison of the prevalence of antibodies to human
herpesvirus 8 (Kaposi's sarcoma-associated herpesvirus) in Brazil and Colorado. J Infect
Dis. 1998; 178:1488-91.
18
113.
Saag MS, Sonnerborg A, Torres RG, Lancaster D, Gazzard BG, Schooley RT, Romero C,
Kelleher D, Spreen W, LaFon S and the Abacavir Phase 2 Clinical Team. Antiretroviral
Effect and Safety of Abacavir Alone and in Combination with Zidovudine in HIV-Infected
Adults. AIDS. 1998; 12:F203-9.
114.
Fitzpatrick LK, Gwanzura L, Zhang X, Mason P, Chikuni O, Schooley R and Katzenstein
D. Epidemiologic Studies of Human Herpes Virus-8 in Zimbabwe. J Acquired Immune
Deficiency Syndromes & Human Retrovirology. 1998; 17:A14.
115.
Zhang XQ, Schooley, RT and Gerber JG. The Effect of Increasing –Acid Glycoprotein
Concentration on the Antiviral Efficacy of Human Immunodeficiency Virus Protease
Inhibitors. J Infect Dis. 1999; 180:1833-7.
116.
Haubrich R, Thompson M, Schooley RT, Lang W, Stein A, Sereni D, van der Ende ME,
Antunes F, Richman D, Pagano G, Kahl L, Fetter A, Brown DJ, Clumeck N, and the
Amprenavir PROAB2002 Study Team. A phase II safety and efficacy study of amprenavir
in combination with zidovudine and lamivudine in HIV-infected patients with limited
antiretroviral experience. AIDS. 1999; 13:2411-20.
117.
Campbell TB, Fitzpatrick L, MaWhinney S, Zhang X and Schooley RT. Human
Herpesvirus 8 (Kaposi's Sarcoma-Associated Herpesvirus) Infection in Men Receiving
Treatment for HIV-1 Infection. J Acquired Immune Deficiency Syndromes & Human
Retrovirology. 1999; 22:333.
118.
Schooley RT, Mladenovic J, Sevin A, et al. Reduced mobilization of CD34+ stem cells in
advanced human immunodeficiency virus type 1 disease. J Infect Dis 2000; 181:148-157.
119.
Schooley RT. Spino C. Kuritzkes D. Walker BD. Valentine FA. Hirsch MS. Cooney E.
Friedland G. Kundu S. Merigan TC Jr. McElrath MJ. Collier A. Plaeger S. Mitsuyasu R.
Kahn J. Haslett P. Uherova P. deGruttola V. Chiu S. Zhang B. Jones G. Bell D. Ketter
N. Twadell T. Chernoff D. Rosandich M. Two double-blinded, randomized, comparative
trials of 4 human immunodeficiency virus type 1 (HIV-1) envelope vaccines in HIV-1infected individuals across a spectrum of disease severity: AIDS Clinical Trials Groups 209
and 214. J Infect Dis. 2000; 182:1357-64.
120.
Fahey JL. Aziz N. Spritzler J. Plaeger S. Nishanian P. Lathey JL. Seigel J. Landay AL.
Kilarui R. Schmitz JL. White C. Wara DW. Akridge R. Cutili J. Douglas SD. Reuben J.
Shearer WT. Nokta M. Polland R. Schooley R. Asthana D. Mizrachi Y. Waxdal M.
Need for an external proficiency testing program for cytokines, chemokines, and plasma
markers of immune activation. Clin & Diag Lab Immun. 2000; 7:540-8.
121.
Campbell TB. Sevin A. Coombs RW. Peterson GC. Rosandich M. Kuritzkes DR.
Mladenovic J. Landay A. Wong R. Ambruso D. Miles S. Pomerantz RJ. Schooley RT.
Changes in human immunodeficiency virus type 1 virus load during mobilization and
harvesting of hemopoietic progenitor cells. Adult AIDS Clinical Trials Group 285 Study
Team. Blood. 2000; 95:48-55.
19
122.
Campbell TB, Borok M, Gwanzura L, MaWhinney S, White IE, Ndemera B, Gudza I,
Fitzpatrick L and Schooley RT. Relationship of human herpesvirus 8 peripheral blood virus
load and Kaposi's sarcoma clinical stage. AIDS. 2000; 14:2109-16.
123.
Schooley RT. Clumeck N. Haubrich R. Thompson M. Danner SA. van Der Ende ME.
Sereni D. Antunes F. Blake D. Myers RE. Tisdale M. Millard J. Mustafa N. Nacci P. A
dose-ranging study to evaluate the antiretroviral activity and safety of amprenavir alone and
in combination with abacavir in HIV-infected adults with limited antiretroviral experience.
Antiviral Therapy. 2001; 6:89-96.
124.
Connick E. Schlichtemeier RL. Purner MB. Schneider KM. Anderson DM. MaWhinney
S. Campbell TB. Kuritzkes DR. Douglas JM Jr. Judson FN. Schooley RT. Relationship
between human immunodeficiency virus type 1 (HIV-1)-specific memory cytotoxic T
lymphocytes and virus load after recent HIV-1 seroconversion. J Infect Dis. 2001;
184:1465-9.
125.
Schacker T. Little S. Connick E. Gebhard K. Zhang ZQ. Krieger J. Pryor J. Havlir D.
Wong JK. Schooley RT. Richman D. Corey L. Haase AT. Productive infection of T cells
in lymphoid tissues during primary and early human immunodeficiency virus infection. J
Infect Dis. 2001; 183:555-62.
126.
Burman WJ, Reves RR, Cohn DL and Schooley RT. Breaking the Camel's Back:
Multicenter Clinical Trials and Local Institutional Review Boards. Ann Intern Med. 2001;
134:152-7.
127.
Schooley RT, Ruane P, Myers RA, Beall G, Lampiris H, Berger D, Chen SS, Miller MD,
Isaacson E and Cheng AK for the Study 902 Team. Tenofovir DF in antiretroviralexperienced patients: results from a 48-week, randomized, double-blind study. AIDS.
2002; 16:1257-63.
128.
Margot NA, Isaacson E, McGowan I, Cheng AK, Schooley RT and Miller MD. Genotypic
and phenotypic analyses of HIV-1 in antiretroviral-experienced patients treated with
tenofovir DF. AIDS. 2002; 16:1227-35.
129.
Garcia R, Schooley RT, Badaro R. An adherence trilogy is essential for long-term HAART
success. Braz J Infect Dis. 2003;7:307-14.
130.
Campbell TB, Rapaport E, Schooley RT and Kuritzkes DR. Increased replication of HIV-1
minor variants during hematopoietic stem-cell mobilization with filgrastim. J Infect Dis
2004; 190: 257-66.
131.
Neid JM, Schooley RT and Campbell TB. Stimulation of Kaposi’s Sarcoma-associated
Herpesvirus Viremia During Hematopoietic Stem Cell Mobilization with Filgrastim.
Blood. 2004. 190: 257-66.
132.
Schooley, RT. HIV and hepatitis C virus coinfection: bad bedfellows. Top HIV Med.
2005;13:112-6
20
133.
Zhang X-Q, Sorensen M, Fung M and Schooley RT. Synergistic in vitro antiretroviral
activity of a humanized monoclonal anti-CD4 antibody (TNX355) and enfuvirtide.
Antimicrobial Agents and Chemother. 2006; 50: 2231-3.
134. Garcia R, Badaró R, Netto EM, Silva M, Amorin FS, Ramos A, Vaida F, Brites C and
Schooley RT Cross-sectional study to Evaluate Factors Associated with Adherence
To Antiretroviral Therapy by Brazilian HIV Infected Patients. AIDS and Related Human
Retroviruses. 2006; 22: 1248-52.
135.
Frey G, Rits-Volloch S, Zhang X-Q , Schooley RT, Chen B, Harrison SC. Small molecules
that bind the inner core of gp41. Proc Nat Acad Sci USA 2006;103:13938-43.
136. Sailer CA, Pott GB, Dinarello CA, MaWhinney S, Forster JE, Larson-Duran JK, Landay A,
Al-Harthi L, Schooley RT, Benson CA, Judson FN, Thompson M, Palella FJ and Shapiro L.
Whole Blood Interleukin-18 Concentration During Early HIV-1 Infection is Associated
with Reduced CXCR4 Coreceptor Expression and Interferon (IFN)γ Levels. J Infect Dis.
2007; 195: 734-8.
137.
Wyles DW, Kaihara KA, Vaida F and Schooley RT. Synergy of small molecular inhibitors of
HCV replication directed at multiple viral targets. J Virol. 2007; 81:3005-8.
138. Al-Harthi L, MaWhinney S, Connick E, Schooley RT, Forster JE, Benson CA, Thompson M,
Judson F, Palella F and Landay A. Immunophenotypic alterations in acute and early HIV
infection. Clin Immunol 2007; 125: 299-308.
139. Grünberger C, Wyles DL, Kaihara KA, and Schooley RT. Three-Drug synergistic interactions
of small molecular inhibitors of Hepatitis C virus (HCV) replication. J Infect Dis 2008.
197: 42-5.
140. Wyles DL, Kaihara KA and Schooley RT. Synergy of an HCV NS4A Antagonist in
Combination with HCV protease and polymerase inhibitors. Antimicrobial Agents
Chemother, 2008, 52:1862-4.
141. Wilson CC, Newman MJ, Livingston BD, Forster JF, MaWhinney S, Scott J, Schooley RT
and Benson CA, Clinical Phase 1 Safety and Immunogenicity Testing of an Epitope-based
DNA Vaccine in HIV-1-infected Subjects Receiving Highly Active Antiretroviral Therapy
(HAART) Clin Vaccine Immunol, 2008 6:986-94.
142. Mehta SR, Huang R, Yang M, Zhang X-Q, Kolli B, Chang K-P, Hoffman RM, Goto Y,
Badaro B and Schooley RT. Real time GFP imaging in a murine leishmaniasis model: a
new tool for leishmania vaccine and drug discovery. Clin Vaccine Immunol. 12: 1764-70;
2008.
143.
Wyles DW, Kaihara KA, Korba BE, Schooley RT, Beadle JR and Hostetler KY. ODE-(S)HPMP is a potent and selective inhibitor of Hepatitis C Virus replication in Genotype 1A,
1B and 2A replicons. Antimicrobial Agents Chemother. 2009;53:2660-2.
21
144. Kumarasamy N, Madhavan V, Venkatesh KK, Saravanan S, Kantor R, Balakrishnan P,
Devaleenol B, Poongulali S, Yepthomi T, Solomon S, Mayer K, Benson C and Schooley
R. High frequency of clinically significant mutations following first-line generic HAART
failure: Implications for second line options in resource-limited settings. Clin Infect Dis.
2009;49:306-9.
145. Lu Q, Zhang X-Q, Pond SLK, Reed SL, Schooley RT, Liu Y-T, Detection in 2009 of the
Swine-Origin Influenza A (H1N1) Virus by a Subtyping Microarray. J Clin Micro 2009;
47: 3060-1.
146. Asmuth DM, Murphy RL, Rosenkranz SL, Lertora JJ, Kottilil S, Cramer Y, Chan ES,
Schooley RT, Rinaldo CR, Thielman N, Li XD, Wahl SM, Shore J, Janik J, Lempicki RA,
Simpson Y, Pollard RB; AIDS Clinical Trials Group A5192 Team. Safety, tolerability, and
mechanisms of antiretroviral activity of pegylated interferon Alfa-2a in HIV-1monoinfected participants: a phase II clinical trial. J Infect Dis. 2010; 201:1686-96.
147. Chen C-H, Zhang X-Q, Lo C-W, Liu Y-T, Gallo RL, Hsien M-F, Schooley RT and ChunMing Huang. The essentiality of alpha-2-macroglobulin in human salivary innate immunity
against new H1N1 swine origin influenza A virus. Proteomics. 2010; 10:2396-401.
148. Rodwell TC, Robertson A, Vera A, Anderson C; Lozada R, Aguirre N, Chait L, Schooley
RT, Zhang, X-Q, Strathdee S. Rapid Response Survey of Influenza A (H1N1) in
Marginalized Populations in Tijuana, Mexico: Lessons Learned. Emerging Infect Dis,
2010;16:1292-5.
149. Schooley RT, Spritzler J, Wang H, Lederman MM, Havlir D, Kuritzkes DR, Pollard RB,
Battaglia C, Robertson M, Mehrotra D, Casimiro D, Cox K, Schock B and the ACTG 5197
Study Team ACTG 5197: A Placebo Controlled Trial of Immunization of HIV-1 Infected
Persons with a Replication Deficient Ad5 Vaccine Expressing the HIV-1 Core Protein J
Infect Dis, 2010;202:705-16.
150. Borok M, Fiorillo S, Gudza I, Putnam B,, Ndemera B, White IE, Gwanzura L, Schooley RT,
Campbell TB. Evaluation of Plasma Human Herpesvirus 8 DNA as a Marker of Clinical
Outcomes During Antiretroviral Therapy of AIDS-related Kaposi's Sarcoma in
Zimbabwe. Clin Infect Dis. 2010;51:342-9. PMID: 20572760
151. Lockman S, Hughes M, McIntyre J, Zheng Y, Chipato T, Conradie F, Sawe F, Asmelash A,
Hosseinipour M, Mohapi L, Stringer E, Mngqibisa R, Siika A, Atwine D, Hakim J, Shaffer
D, Kanyama C, Wools-Kaloustian K, Salata R, Hogg E, Alston-Smith B, Walawander A,
Purcelle-Smith E, Eshleman S, Rooney J, Rahim S, Mellors J, Schooley R, Currier J. A
Trial of Two Antiretroviral Therapies in Women with and without Prior Nevirapine Use.
New Engl J Med, 363:1499-509.
152. Mehta SR, Zhang X-Q, Badaro R, Spina C, Day J, Chang K-P and Schooley RT. Flow
Cytometric Screening for Anti-Leishmanials in a Human Macrophage Cell Line.
Experimental Parasitology, 2010; 126: 617-20.
22
153. Thompson MA (Panel Chair), Aberg JA, Cahn P, Montaner JSG, Rizzardini G, Telenti A,
Gatell JM, Günthard HF, Hammer SM, Hirsch MS; Jacobsen DM, Reiss P, Richman DD,
Volberding PA, Yeni P, Schooley RT (Panel Vice-Chair). Antiretroviral Treatment of Adult
HIV Infection: 2010 Recommendations of the International AIDS Society-USA Panel.
JAMA. 2010; 304; 321 – 33.
154. Meditz AL, MaWhinney S, Allshouse A, Feser W, Markowitz M, Little S, Hecht R, Daar ES,
Collier AC, Margolick J, Kilby JM, Routy J-M, Conway B, Kaldor J, Levy J, Schooley R,
Cooper DA, Altfeld M, Richman D, Connick E. Sex, Race, and Geographic Region
Influence Clinical Outcomes Following Primary HIV-1 Infection. J Infect Dis. 2011;
140:755-60
155. Li JZ, Brumme ZL, Brumme CJ, Wang H, Spritzler J, Robertson M, Lederman MM, Mary
Carrington M, Walker BD, Schooley RT, Kuritzkes DR and the AIDS Clinical Trials Group
A5197 Study Team. Factors Associated with Viral Rebound in HIV-Infected Individuals
Enrolled in a Therapeutic HIV-1 gag Vaccine Trial. J Infect Dis, 2011; 203:976-83.
156. Recommendations on sequence and phenotypic analysis for resistance monitoring in hepatitis
C virus drug development: Consensus from the HCV DRAG. Sequence Analysis Working
Group (SAWG) and Phenotype Analysis Working Group (PAWG). Kwong AD, Najera I,
Bechtel J, Bowden S, Fitzgibbon J, Harrington P, Kempf D, Kieffer TL, Koletzki D ,
Kukolj G, Lim S, Pilot-Matias T, Lin K, Mani N, Mo H, O’Rear J, Otto M, Parkin N,
Pawlotsky J-M, Petropoulos C, Picchio G, Ralston R, Reeves JD, Schooley RT, Seiwert S,
Standring S, Stuyver L, Sullivan J, Miller V under the auspices of the Forum for
Collaborative HIV Research and on behalf of the HCV Drug Development Advisory Group
(HCV DRAG). Gastroenterology. 2011; 140:755-60
157. Holmes EC, Ghedin E, Halpin RA, Stockwell TB, Zhang, X-Q, Fleming R, Davey R, Benson
CA, Mehta SR, Taplitz RA, Liu Y-T, Brouwer KC, Wentworth DE, Lin X, INSIGHT
FLU002 Study Group and Schooley RT. Extensive Geographical Mixing of Human
H1N1/09 Influenza A Virus in a Single University Community. J Virol, 2011; 14; 6923-9.
158. Valiaeva N, Wyles DL, Schooley RT, Hwu JB, James R. Beadle JR Prichard MN, Hostetler
KY. Synthesis and antiviral evaluation of 9-(S)-[3-alkoxy-2(phosphonomethoxy)propyl]nucleoside alkoxyalkyl esters: Inhibitors of hepatitis C virus
and HIV-1 replication. Bioorganic and Med Chem, 2011: 19; 4616-25.
159. Rodrigues MAZ, Grassi MFR, Mehta SR, Zhang X-Q, Gois LL, Schooley RT and Badaro R.
Th1/Th2 Cytokine Profile in HIV and Leishmania Co-infected patients in Brazil. Clin
Vaccine Immunol 2011.49:3584-90.
160. Lochhead MJ, Todorof K, Delaney M, Ives JT, Greef C, Moll K, Rowley K, Vogel K, Myatt
C, Zhang XQ, Logan C, Benson C, Reed S, Schooley RT. Rapid multiplexed immunoassay
for simultaneous serodiagnosis of HIV-1 and coinfections. J Clin Microbiol. 2011;49:358490.
161. Zhu H, Wong-Staal F, Lee H, Syder A, McKelvy J, Schooley RT, Wyles DL.
23
Evaluation of ITX 5061, a scavenger receptor B1 antagonist: resistance selection and
activity in combination with other hepatitis C virus antivirals. J Infect Dis. 2012; 205:65662.
162. Manion M, Rodriguez B, Medvik K, Hardy G, Harding CV, Schooley RT, Pollard R, Asmuth
D, Murphy R, Barker E, Brady KE, Landay A, Funderburg N, Sieg SF, Lederman MM.
Interferon-alpha administration enhances CD8+ T cell activation in HIV infection.
PLoS One. 2012;7:e30306.
163. Lorenzana SB, Hughes MD, Grinsztejn B, Collier AC, Luz PM, Freedberg KA, Wood R,
Levison JH, Mugyenyi PN, Salata R, Wallis CL, Weinstein MC, Schooley RT, Walensky
RP. Genotype assays and third-line ART in resource-limited settings: a simulation and costeffectiveness analysis of a planned clinical trial. AIDS. 2012;26:1083-1093.
164. Mistro S, Maciel Ide M, de Menezes RG, Maia ZP, Schooley RT, Badaró R. Does Lipid
Emulsion Reduce Amphotericin B Nephrotoxicity? A Systematic Review and Metaanalysis. Clin Infect Dis. 2012;54:1774-7.
165. Li JZ, Brumme CJ, Lederman MM, Brumme ZL, Wang H, Spritzler J, Carrington M, Medvik
K, Walker BD, Schooley RT, Kuritzkes DR; AIDS Clinical Trials Group A5197 Study
Team. Characteristics and outcomes of initial virologic suppressors during analytic
treatment interruption in a therapeutic HIV-1 gag vaccine trial. PLoS One. 2012; 7, e34134.
166. Orlov M, Vaida F, Finney OC, Smith DM, Talley AK, Wang R, Kappe SH, Deng Q,
Schooley RT *, Duffy PE. P. falciparum Enhances HIV Replication in PBMCs Isolated
from Humans Undergoing an Experimental Malaria Challenge PLoS One, 2012; 7: e39000.
doi:10.1371 * corresponding author.
167. Saravanan S, Madhavan V, Kantor R, Sivamalar S, Giomathi S, Solomon SS, Kumarasamy
N, Smith DM, Schooley RT, Solomon S, Balakrishnan P. Unusual Insertion and Deletion
at Codon 67 and 69 of HIV-1 Subtype C Reverse Transcriptase Among First-Line Highly
Active Antiretroviral Treatment Failing South Indian Patients: Association with Other
Resistance Mutations. AIDS Res Hum Retroviruses, 2012;28:1763-5. doi:
10.1089/AID.2011.0331. Epub 2012 May 21..
168. Lockman S, Hughes M, Sawe F, Zheng Y, McIntyre J, Chipato T, Asmelash A, Rassool M,
Kimaiyo S, Shaffer D, Hosseinipour M, Mohapi L, Ssali F, Chibowa M, Amod F, Halvas E,
Hogg E, Alston-Smith B, Smith L, Schooley R, Mellors J, Currier J, the OCTANE (Optimal
Combination Therapy After Nevirapine Exposure) ACTG A5208/OCTANE StudyTeam.
Nevirapine- Versus Lopinavir/Ritonavir-Based Initial Therapy for HIV-1 Infection among
Women in Africa: A Randomized Trial. PLoS Medicine, 2012; 9: e1001236.
169. Li JZ, Brumme CJ, Lederman MM, Brumme ZL, Wang H, Spritzler J, Carrington M, Medvik
K, Walker BD, Schooley RT, Kuritzkes DR; AIDS Clinical Trials Group A5197 Study
Team. Characteristics and outcomes of initial virologic suppressors during analytic
treatment interruption in a therapeutic HIV-1 gag vaccine trial. PLoS One. 2012;7:e34134.
doi: 10.1371/journal.pone.0034134. Epub 2012 Mar 30.
24
170. Noormahomed EV, Orlov M, do Rosario V, Petersen BW, Guthrie C, Badaro R, Schooley
RT. A cross-sectional study of sub-clinical Plasmodium falciparum infection in HIV-1
infected and uninfected populations in Mozambique, South-Eastern Africa. Malar J.
2012;11:252. doi: 10.1186/1475-2875-11-252. PMID: 22853699
171. Campbell TB, Smeaton LM, Kumarasamy N, Flanigan T, Klingman KL, Firnhaber C,
Grinsztejn B, Hosseinipour MC, Kumwenda J, Lalloo U, Riviere C, Sanchez J, Melo M,
Supparatpinyo K, Tripathy S, Martinez AI, Nair A, Walawander A, Moran L, Chen Y,
Snowden W, Rooney JF, Uy J, Schooley RT, De Gruttola V, Hakim JG; PEARLS study
team of the ACTG. Efficacy and safety of three antiretroviral regimens for initial treatment
of HIV-1: a randomized clinical trial in diverse multinational settings. PLoS Med.
2012;9(8):e1001290. Epub 2012 Aug 14. PMID: 22936892
172. Saravanan S, Madhavan V, Balakrishnan P, Smith DM, Solomon SS, Sivamalar S, Poongulali
S, Kumarasamy N, Schooley RT, Solomon S, Kantor R. Darunavir Is a Good Third-Line
Antiretroviral Agent for HIV Type 1-Infected Patients Failing Second-Line Protease
Inhibitor-Based Regimens in South India. AIDS Res Hum Retroviruses. 2013;29:630-2.
doi: 10.1089/AID.2011.0334. Epub 2012 Dec 7. PMID:23045961
173. Logan C, Givens M, Ives JT, Delaney M, Lochhead MJ, Schooley RT, Benson CA.
Performance evaluation of the MBio Diagnostics point-of-care CD4 counter. J Immunol
Methods. 2013;387:107-13. doi: 10.1016/j.jim.2012.10.002. Epub 2012 Oct 11. PMID:
23063690.
II. Invited Articles, Book Chapters, Review Articles, Edited Books, Editorials and Monographs.
1.
Schooley RT and Dolin R. Epstein-Barr Virus (Infectious Mononucleosis) In: Principles
and Practice of Infectious Diseases, John Wiley and Sons, New York. 1979; 1324-41.
2.
Schooley RT and Hirsch MS. Epstein-Barr Virus: Current Concepts. Infect Disease
Practice.1980; 3:1-7.
3.
Schooley RT, Parrillo JE, Wolff SM and Fauci AS. Management of the idiopathic
hypereosinophilic syndrome. In: The Eosinophil. Mahmood AAF, and Austin KF, Eds,
Grune and Stratton. 1980; 323-43.
4.
Hirsch MS, Cheeseman SH, Rubin RH, Schooley RT, Henle W, Lennette ET, Andrews C,
Shah KV and Cantell K. Prophylactic interferon-alpha (IFN-) in renal transplant recipients.
In: The Biology of the Interferon System, DeMaeyer E, Galasso G and Schellekens H, eds.
Elsevier/North-Holland. Biomedical Press. 1981.
5.
Schooley RT. Infectious Mononucleosis: Etiology. In: Infectious Mononucleosis.
Schlossberg D, ed. Praeger Scientific. New York, 1982; 1-13.
6.
Southwick FS and Schooley RT. Infectious Diseases. In: Blackshear PS, ed. Key
References in Internal Medicine. New York: Churchill Livingstone, 1982.
25
7.
Hirsch MS, Schooley RT, Rubin RH, Tolkoff-Rubin NE and Cantell K. Interferon in renal
transplant recipients. In: Interferons UCLA Symposia on Molecular and Cellular Biology.
Merigan TC and Friedman RM. 1982; 25:421-5.
8.
Schooley RT. Susceptibility to Acquired Immune Deficiency Syndrome (AIDS): Clinical
Practice Update. Volume 2, Number 4, February 21, 1983.
9.
Hirsch MS and Schooley RT. Drug Therapy. Treatment of herpesvirus infections. N Engl
J Med. 1983; 309:963-70, 1034-9.
10.
Schooley RT: How to manage infectious mononucleosis. Drug Therapy. December, 1983;
13:68-77.
11.
Hirsch MS, Schooley RT, Ho DD and Kaplan JC. Possible Viral Interactions in the
Acquired Immunodeficiency Syndrome (AIDS). Rev Infect Dis. 1984; 6:726-31.
12.
Schooley RT, Hirsch MS, Rubin RH and Cantell K. The role of interferons in viral
infections in immune compromised patients. In: Transplantation and Blood Transfusion.
C. Th. Smit Sibinga, P. C. Das, G. Opelz. 1984; 83-9.
13.
Schooley RT and Dolin R. Epstein-Barr Virus (Infectious Mononucleosis). In: Principles
and Practice of Infectious Diseases, John Wiley and Sons, New York, Second Edition.
1984; 971-82.
14.
Hirsch MS and Schooley RT. Interferon trials in immunocompromised patients. In: The
Biology of the Interferon System. Kirchner H and Schellekens H. ed. Amsterdam. Elsevier,
1985.
15.
Blumberg RS and Schooley RT. Lymphocyte markers and infectious diseases. Seminars in
Hematology. 1985; 22:81-114.
16.
Vogt MW, Addison R, Schooley RT and Hirsch MS. Are apheresis personnel at risk for
AIDS Plasma Therapy & Transfusion Technology. 1986; 7:515-20.
17.
Schooley RT. Epstein Barr virus infections, including mononucleosis in Harrison's
Textbook of Internal Medicine. 11th Edition, McGraw-Hill, New York. 1987; 699-703.
18.
Schooley RT. AIDS In: Primary Care Medicine. 2nd Edition, Lippincott, Philadelphia,
AM Gorell, LA May, AG Mulley (Ed). 1987; 637-41.
19.
Vogt MW and Schooley RT. An overview of antiviral therapy of HTLV-III/LAV infection.
Noyes Publications. 1987.
20.
Schooley RT. Encephalitis. In: Neurological and Neurosurgical Intensive Care. A. H.
Ropper and S. F. Kennedy, Aspen Publication, Rockville, Maryland, Second Edition. 1988;
289-307.
26
21.
Schooley RT. Prophylactic and Therapeutic perspective in viral infections In: Infections in
Transplant Patients. Georg Thieme Verlag Stuttgart, 1987; 205-24.
22.
Schooley RT, Blumberg RS, Vogt M, Hartshorn K and Hirsch MS. Therapeutic
perspectives in human immunodeficiency virus infection. J Exp Pathol. 1987; 3:661-80.
23.
Vogt M, Schooley RT and Hirsch MS. Chemotherapie und immunoprophylaxe der HIVinfektion. Schweizerische Rndschau fur Medizin Praxis. 1986; 75:1471-5.
24.
Schooley RT. Perspectives for lymphokine therapy: from genetic engineering to
immunologic engineering. 1987, C. Th. Smit Sibinga, P.D. Das, C. P. Engelfriet, Editors.
Nijhoff Publishing. 131-42.
25.
Pomerantz RJ and Schooley RT. Therapy of Human Immunodeficiency Virus Infections.
Clinics in Laboratory Medicine. 1987; 7:793-813.
26.
Schooley RT. Interferon Alpha in the Therapy of Patients with HW Infections. In: HIV
and Other Highly Pathogenic Viruses, Academic Press Inc. Roberts A. Smith, Eds. 1987;
113-24.
27.
Sibinga CT, de Vries B, McShine RL, Das PC and Schooley RT. HIV antibody screening
in a low-risk population (blood donors) [letter]. Transfusion. 1987; 27:215-6.
28.
Schooley RT. The Quest for an AIDS Vaccine. N Engl J Public Policy. 1988; 135-44.
29.
Schooley RT. AIDS: Clinical Aspects and Biologic Therapies. Immunology and Allergy
Clinics. 1988; 93-109.
30.
Schooley RT. Chronic Fatique Syndrome: A Manifestation of Epstein-Barr Virus
Infection? In: Current Clinical Topics in Infectious Diseases. JS Remington and MN
Swartz, McGraw-Hill Book Co. 1988; 9:126-46.
31.
Schooley RT. Morbidity in Compromised Patients Due to Viruses Other Than Herpes
Group and Hepatitis Viruses. In: Clinical Approach to Infection in the Compromised Host.
2nd Edition. RH Rubin and LS Young. Plenum Book Company, New York and London.
1988.
32.
Schooley RT. Waltzing HIV-tilda (editorial). Arch Intern Med. 1988; 148(4):778.
33.
Pomerantz RJ and Schooley RT. Therapy of human immunodeficiency virus infections.
Clin Lab Med. 1987; 7(4):793-813.
34.
Hirsch MS and Schooley RT. Resistance to antiviral drugs: the end of innocence
(editorial). N Engl J Med. 1989; 320(5):313-4.
35.
Schooley RT. Epstein-Barr virus. Current Opinion in Infectious Diseases. 1989; 2:267-71.
27
36.
Schooley RT and Dolin R. Epstein-Barr Virus (Infectious Mononucleosis). In: Principles
and Practice of Infectious Diseases, John Wiley and Sons, New York, Third Edition. 1989;
1172-85.
37.
Johnson RP and Schooley RT. Update on antiretroviral agents other than zidovudine.
AIDS. 1989; 3:S 145-51.
38.
Schooley RT. Infectious Mononucleosis. In: Merck Manual of Diagnosis and Theapy.
Merck Sharp & Dohme Research Laboratories, Rahway, NJ. 15th Edition.
39.
Schooley RT. Cytomegalovirus in the setting of infection with human immunodeficiency
virus. Rev Infect Dis. 1990; 12:S811-9.
40.
Schooley RT, Strongin W and Hawley P. Methodological issues in AIDS clinical trials.
Discussion. Design of clinical trials-end points. J Acquir Immune Defic Syndr. 1990;
3:S72-6.
41.
Schooley RT. Pneumonia Due to Herpesviruses. In: Respiratory Disease in the
Immunosuppressed Host. J Shelhamer, et al. J. B. Lippincott Company, Philadelphia.
1991; 386-97.
42.
Schooley RT. Challenges in the clinical development of antiretroviral drugs. Antiviral
Research. 1992; 17:305-10.
43.
Fahey JL and Schooley RT. Status of immune-based therapies in HIV infection and AIDS.
Clin Exp Immunol. 1992; 88:1-5.
44.
Schooley RT. Encephalitis. In: Neurological and Neurosurgical Intensive Care, Third
Edition, A.H. Ropper, Raven Press, New York. 1992; 411-35.
45.
Schooley RT. Herpesvirus Infection in Individuals with HIV Infection. In: AIDS:
Etiology, Diagnosis, Treatment, and Prevention, Third Ed, V.T. DeVita, S. Hellman and
S.A. Rosenberg, J.B. Lippincott Company, Philadelphia. 1992; 193-207.
46.
Schooley RT. Antiretroviral Chemotherapy. In: AIDS and Other Manifestations of HIV
Infection. G.P. Wormser, Raven Press, New York. 1992; 609-23.
47.
Schooley RT. Just (Don't) Do It. J Clin Invest. 1993; 92:535.
48.
Connick E and Schooley RT. HIV-1 Specific Immune Responses. In: HIV Molecular
Organization, Pathogenicity and Treatment. W.J.W. Morrow and N. Haigwood. Elsevier
Science Publishers, The Netherlands. 1993; 75-98.
49.
Schooley RT. Immune Based Therapies for HIV-1 Infection. In: Textbook of AIDS
Medicine. S. Broder, D.P. Bolognesi and T.C. Merigan, Jr. Williams and Wilkins,
Baltimore. 1994; 713-20.
28
50.
Schooley RT. Chronic Fatigue Syndrome. In: Principles and Practice of Infectious
Diseases, John Wiley and Sons, New York, Fourth Edition, 1994.
51.
Schooley RT and Dolin R. Epstein-Barr Virus (Infectious Mononucleosis). In: Principles
and Practice of Infectious Diseases, John Wiley and Sons, New York, Fourth Edition, 1994.
52.
Schooley RT. Correlation between viral load measurements and outcome in clinical trials
of antiviral drugs. AIDS. 1995; 9:S15-9.
53.
Schooley RT. HIV-1 specific cytotoxic T-cell responses. AIDS. 1995; 9:S113-6.
54.
Schooley RT. Immunomodulatory effects of antiretroviral chemotherapy. J Biol Regul
Homeost Agents. 1995; 9:110-3.
55.
Schooley RT. Enhancing HIV-1 Specific Immunity as a Therapeutic Strategy in AIDS.
Advances in Exper Med and Biol. 1996; 394:405-10.
56.
Benson EM, French MA and Schooley RT. Managing HIV. Part 4: Primary
therapy. 4.2 Immune-based therapy for HIVinfection. Med J Australia. 1996; 164:297300.
57.
Carpenter CC, Fischl MA, Hammer SM, Hirsch MS, Jacobsen DM, Katzenstein DA,
Montaner JS, Richman DD, Saag MS, Schooley RT, Thompson MA, Vella S, Yeni PG and
Volberding PA. Antiretroviral therapy for HIV infection in 1996. Recommendations of an
international panel. International AIDS Society-USA. JAMA. 1996; 276:146-54.
58.
Cotton D, Bartlett J, Schooley R, Gulick R. Therapeutic decision making in 1997.
59.
Schooley RT. Check, but not checkmate. Antiviral Therapy. 1997; 2:68-9.
60.
Carpenter CC, Fischl MA, Hammer SM, Hirsch MS, Jacobsen DM, Katzenstein DA,
Montaner JS, Richman DD, Saag MS, Schooley RT, Thompson MA, Vella S, Yeni PG and
Volberding PA. Antiretroviral therapy for HIV infection in 1997. Updated
recommendations of the International AIDS Society-USA panel. JAMA. 1997; 277:19629.
61.
Carpenter CC, Feinberg M, Schooley RT, (23 panel members). Report of the NIH Panel to
Define Principles of Therapy of HIV Infection and Guidelines for the Use of Antiretroviral
Agents in HIV-Infected Adults and Adolescents. Ann lntern Med. 1998; 128:1057-1100.
62.
Carpenter CC, Fischl MA, Hammer SM, Hirsch MS, Jacobsen DM, Katzenstein DA,
Montaner JS, Richman DD, Saag MS, Schooley RT, Thompson MA, Vella S, Yeni PG and
Volberding PA. Antiretroviral therapy for HIV infection in 1998. Updated
recommendations of the International AIDS Society-USA panel. JAMA. 1998; 280:78-86.
63.
Saag MS and Schooley RT. Antiretroviral chemotherapy. Curr Clin Top Infect Dis. 1998;
18:154- 79.
29
64.
Schooley, RT. Longer-term immunologic effects and side effects of successful
antiretroviral therapy. Clin Infect Dis. 1999; 29:12-8.
65.
Carpenter CC, Cooper DA, Fischl MA, Gatell JM, Gazzard BG, Hammer SM, Hirsch MS,
Jacobsen DM, Katzenstein DA, Montaner JS, Richman DD, Saag MS, Schechter M,
Schooley RT, Thompson MA, Vella S, Yeni PG and Volberding PA. Antiretroviral
Therapy in Adults. Updated recommendations of the International AIDS Society - USA
Panel. JAMA. 2000; 283:381-90.
66.
Yeni PG, Hammer SC, Carpenter CC, Cooper DA, Fischl MA, Gatell JM, Gazzard BG,
Hirsch MS, Jacobsen DM, Katzenstein DA, Montaner JS, Richman DD, Saag MS,
Schechter M, Schooley RT, Thompson MA, Vella S and Volberding PA. Antiretroviral
Treatment for Adult HIV Infection in 2002: Updated recommendations of the International
AIDS Society - USA Panel. JAMA. 2002; 288:222-35.
67.
Schooley RT. Antiretroviral Chemotherapy. In: AIDS and Other Manifestations of HIV
Infection. (Fourth Edition) G.P. Wormser, Raven Press, New York. 2002; 827-840.
68.
Yeni PG, Hammer SC, Hirsch MS, Saag MS, Schechter M, Carpenter CCJ, Fischl MA,
Gatell JM, Gazzard BG, Jacobsen DM, Katzenstein DA, Montaner JS, Richman DD,
Schooley RT, Thompson MA, Vella S and Volberding PA. Treatment of Adult HIV
Infection: 2004 Recommendations of the International AIDS Society-USA Panel. JAMA.
2004;292: 251-65.
69.
Schooley RT. Starting highly active antiretroviral therapy for HIV infection: is it WIHS to
wait? Ann Intern Med. 2004;140:305-6.
70.
Schooley RT. Human Retroviruses: AIDS and Other Diseases. In Mechanisms of
Microbial Diseases.(Fourth Edition) Engleberg NC, DiRita V and Dermody TS, Eds.
Lippincott Williams and Wilkins. 2006 pp 376-388.
71.
Hammer SM, Saag, MS, Schechter, M, Montaner JSG, Schooley RT, Jacobsen DM,
Thompson MA, Carpenter CCJ, Fischl MA, Gazzard BG, Gatell JM, Hirsch, MS,.
Katzenstein DA, Richman DD; Vella S, Yeni PG, Volberding, PA. Treatment for Adult
HIV Infection: 2006 Recommendations of the International AIDS Society–USA Panel.
JAMA, 2006; 296: 827-43.
72.
Schooley RT. Epstein Barr Virus Infection. In Cecil’s Textbook of Internal Medicine.
2007. In press.
73.
Schooley RT. Viral Load Testing in Resource Limited Settings. Clin Infect Dis. 2007; 44:
139-40.
74.
Schooley RT and Mellors JW. No Cure Yet for HIV-1 But Therapeutic Research Presses
On. J Infect Dis. 2007; 195: 770-2.
75.
Smith DM and Schooley RT. Running with Scissors: Using Antiretroviral Therapy
without Monitoring Viral Load. Clin Infect Dis. 2008; 46: 1598-1600.
30
76.
Grant RM, Hamer D, Hope T, Johnston R, Lange J, Lederman MM, Lieberman J, Miller
CJ, Moore JP, Mosier DE, Richman DD, Schooley RT, Springer MS, Veazey RS,
Wainberg MA. Whether or Wither Microbicides. Science, 2008; 321: 532-4.
77.
Hammer SM, Eron JJ, Reiss P, Schooley RT, Thompson MA, Walmsley S, Cahn P, Fischl,
MA, Gatell JM, Hirsch MS, Jacobsen DM, Montaner JSG, Richman DD, Yeni PG,
Volberding PA. Antiretroviral Treatment of Adult HIV Infection: 2008 Recommendations
of the International AIDS Society–USA Panel. JAMA, 2008; 300:555-70.
78.
DeGruttola V, Little S and Schooley. Controlling the AIDS Epidemic without a Vaccine.
AIDS. 2008; 22:2554-5.
79.
Wilson CC and Schooley RT. Host Responses to Infections in Infectious Diseases, Third
Edition. Mosby Elsevier, London. 2010. pp 30 – 44.
80.
Monto A, Schooley RT, Lai JC, Sulkowski MS, Chung RT, Pawlotsky JM, McHutchison
JG, Jacobson IM. Lessons From HIV Therapy Applied to Viral Hepatitis Therapy:
Summary of a Workshop. Am J Gastroenterol. 2010; 105:989-1004.
81.
Wyles DL and Schooley RT. Rong’s numbers: Accelerating progress in HCV therapeutic
research. Sci. Transl. Med, 2010; 2, 33ps25.
82.
DeGruttola V and Schooley RT. Antiretroviral Therapy as Prevention: Linking the
Mainframe to Main Street. Clin Infect Dis. 2011;52(8):1050-2.
83.
Schooley RT. Hepatitis C virus therapeutics: at the end of the beginning. Top Antivir Med.
2012; 20:17-9.
31
Ongoing Federal Grant Support
Title
Granting Agency
Amount of
Total Award
(direct costs)
Time period of
contract/grant
Role, e.g. PI, coinvestigator,
project leader, etc.
U01 AI074521
Multiplex Nucleic
Acid Detection
Device for the
Diagnosis of
Respiratory Viruses
R01AI076558
Orally Active
Nucleoside
Phosphonates for
Hepatitis C Virus
2T32AI007036-31
Training in
Infectious Diseases
5 P30 AI36214
International Core
for the UCSD
CFAR
NIAID
4,110,114
07/10/0706/30/12
Principal
Investigator
NIAID
1,758,179
04/10/0903/31/14
Principal
Investigator
NIAID
$392,000
9/1/20108/31/2015
Principal
Investigator
NIAID
$1,976,249
6/01/07 –
05/31/12
Co-PI,
International
Core
1R24TW008908-01
Universidade
Eduardo MondlaneUCSD Medical
Education
Partnership
1 UO1 AI069432
San Diego AIDS
Clinical Trials Unit
2R44AI068543
Low Cost MultiPathogenLaser
Diagnostic for HIV
and AIDS CoInfections
2R44AI070052
Low Cost MultiPathogen Laser
Diagnostic for
CD4+ T-Cell
Counting
NIH Fogarty
Center/PEPFAR
~$2 million
9/30/20109/29/2015
Co-Investigator
NIAID
$956,274
12/01/0611/30/13
Co-Investigator
NIAID
841,216
9/1/098/31/12
Co-Investigator
NIAID
$748,823
9/1/098/31/11
Co-Investigator
32